Erste Asset Management GmbH Makes New $360,000 Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Erste Asset Management GmbH acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPTFree Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 50,000 shares of the company’s stock, valued at approximately $360,000.

Several other institutional investors also recently bought and sold shares of EYPT. Patient Square Capital LP purchased a new stake in EyePoint Pharmaceuticals during the third quarter worth approximately $10,882,000. Franklin Resources Inc. lifted its position in shares of EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after purchasing an additional 342,516 shares in the last quarter. abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals during the fourth quarter worth $1,719,000. Finally, Barclays PLC lifted its position in shares of EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after purchasing an additional 197,033 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Price Performance

EYPT stock opened at $6.52 on Friday. EyePoint Pharmaceuticals, Inc. has a 1-year low of $5.54 and a 1-year high of $23.97. The firm has a fifty day moving average price of $7.19 and a two-hundred day moving average price of $8.39. The firm has a market cap of $448.11 million, a price-to-earnings ratio of -3.26 and a beta of 1.41.

EyePoint Pharmaceuticals (NASDAQ:EYPTGet Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $11.60 million for the quarter, compared to the consensus estimate of $11.02 million. As a group, analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on EYPT shares. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

Read Our Latest Stock Report on EyePoint Pharmaceuticals

About EyePoint Pharmaceuticals

(Free Report)

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Featured Stories

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPTFree Report).

Institutional Ownership by Quarter for EyePoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.